Compare CDLX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | XBIT |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 75.0M |
| IPO Year | 2018 | 2015 |
| Metric | CDLX | XBIT |
|---|---|---|
| Price | $1.02 | $2.51 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 27.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $2.09 |
| 52 Week High | $3.28 | $3.61 |
| Indicator | CDLX | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 66.40 |
| Support Level | $1.00 | $2.15 |
| Resistance Level | $1.04 | $2.69 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 39.23 | 81.25 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.